How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

Outbreaks News Archives

Login / Signup

Early Release – Strongyloides Genetic Diversity among Humans, Dogs, and Nonhuman Primates, Central African Republic, 2016–2022 – Volume 32, Number 3—March 2026 – Emerging Infectious Diseases journal

Early Release – Costs of Extrapulmonary Nontuberculous Mycobacteria Disease, Denmark, 2005–2017 – Volume 32, Number 3—March 2026 – Emerging Infectious Diseases journal

Early Release – Optimal Specimens and Lesions for Mpox Diagnosis Using Real-Time PCR, South Korea – Volume 32, Number 3—March 2026 – Emerging Infectious Diseases journal

Early Release – Rickettsia lanei Rickettsiosis, Oregon, USA, 2025 – Volume 32, Number 4—April 2026 – Emerging Infectious Diseases journal

Communicable disease threats report, 21

Early Release – Romanticism at the Edge of Death – Volume 32, Number 3—March 2026 – Emerging Infectious Diseases journal

Early Release – Rethinking Leptospirosis Prevention, the Philippines – Volume 32, Number 3—March 2026 – Emerging Infectious Diseases journal

Early Release – Projected Effects of Changing Global Tuberculosis Epidemiology on Mycobacterium tuberculosis Prevalence and Immunoreactivity, 2024–2050 – Volume 32, Number 3—March 2026 – Emerging Infectious Diseases journal

Early Release – Tuberculosis after TB Preventive Therapy in Persons Living with HIV Recently Initiating Antiretroviral Therapy, Mozambique – Volume 32, Number 3—March 2026 – Emerging Infectious Diseases journal

Early Release – Emerging Endemic Area for Blastomycosis, New York, USA, 2000–2024 – Volume 32, Number 3—March 2026 – Emerging Infectious Diseases journal

Schedule an Appointment

Quick Links

Patient Forms

Contact Us